104 related articles for article (PubMed ID: 1842600)
21. Urinary excretion of deuterated metabolites in patients with tyrosinemia type I after oral loading with deuterated L-tyrosine.
Wadman SK; Duran M; Ketting D; Bruinvis L; van Sprang FJ; Berger R; Smit GP; Steinmann B; Leonard JV; Divry P; Farriaux JP; Cartigny B
Clin Chim Acta; 1983 May; 130(2):231-8. PubMed ID: 6872257
[TBL] [Abstract][Full Text] [Related]
22. ["Succinylacetone effect' after oral homogentisate loading].
Laberge C; Lescault A; Grenier A; Gagné R
Union Med Can; 1981 Jul; 110(7):621-5. PubMed ID: 7292795
[No Abstract] [Full Text] [Related]
23. Persistent succinylacetone excretion after liver transplantation in a patient with hereditary tyrosinaemia type I.
Tuchman M; Freese DK; Sharp HL; Whitley CB; Ramnaraine ML; Ulstrom RA; Najarian JS; Ascher N; Buist NR; Terry AB
J Inherit Metab Dis; 1985; 8(1):21-4. PubMed ID: 2581063
[TBL] [Abstract][Full Text] [Related]
24. Clinical utilization of dried blood spot nitisinone (NTBC) and succinylacetone (SA) concentrations in hereditary tyrosinaemia type 1 - A UK centre experience.
Yeo M; Turner C; Dalton NR; Rahman Y; Vara R
Ann Clin Biochem; 2020 Nov; 57(6):412-419. PubMed ID: 32936663
[TBL] [Abstract][Full Text] [Related]
25. [Congenital disorders of tyrosine metabolism and their correction in children with tumors].
Baĭkova VN; Vares IM; Rybal'chenko VG; Shevchenko VE; Sotnikova EN
Vopr Onkol; 1987; 33(11):42-8. PubMed ID: 3686921
[TBL] [Abstract][Full Text] [Related]
26. Liver transplantation in a 23-year-old tyrosinaemia patient: effects on the renal tubular dysfunction.
Kvittingen EA; Jellum E; Stokke O; Flatmark A; Bergan A; Sødal G; Halvorsen S; Schrumpf E; Gjone E
J Inherit Metab Dis; 1986; 9(2):216-24. PubMed ID: 3091928
[TBL] [Abstract][Full Text] [Related]
27. [Sepsis, as the presenting form of hereditary tyrosinemia type I].
Iglesias Niubo J; Riudor Taravilla E; Goma Brufau AR; Civit Colas MA; Suñé Gracia JM; Bertrán Sanges JM; Gallart Catalá A
An Esp Pediatr; 1988 Sep; 29(3):235-8. PubMed ID: 3057981
[TBL] [Abstract][Full Text] [Related]
28. Tandem mass spectrometric assay of succinylacetone in urine for the diagnosis of hepatorenal tyrosinemia.
Rashed MS; Al-Ahaidib LY; Al-Dirbashi OY; Al Amoudi M; Al-Sayed MM; Rahbeeni Z; Al-Hassnan Z; Al-Dbaas A; Al-Owain M; Ni Luanaigh M
Anal Biochem; 2005 Apr; 339(2):310-7. PubMed ID: 15797572
[TBL] [Abstract][Full Text] [Related]
29. Genotyping of a case of tyrosinaemia type I with normal level of succinylacetone in amniotic fluid.
Poudrier J; Lettre F; St-Louis M; Tanguay RM
Prenat Diagn; 1999 Jan; 19(1):61-3. PubMed ID: 10073910
[TBL] [Abstract][Full Text] [Related]
30. Tyrosinaemia type I with normal levels of plasma tyrosine.
de Almeida IT; Leandro PP; Silva MF; Silveira C; da Silva A; de Sousa JS; Duran M
J Inherit Metab Dis; 1990; 13(3):305-7. PubMed ID: 2122090
[No Abstract] [Full Text] [Related]
31. Deficiency of fumarylacetoacetase in a patient with hereditary tyrosinemia.
Berger R; Smit GP; Stoker-de Vries SA; Duran M; Ketting D; Wadman SK
Clin Chim Acta; 1981 Jul; 114(1):37-44. PubMed ID: 7249373
[TBL] [Abstract][Full Text] [Related]
32. Neonatal and prenatal diagnosis of hereditary tyrosinaemia.
King GS; MacKenzie F; Pettit BR
Lancet; 1983 Jun; 1(8336):1279. PubMed ID: 6134070
[No Abstract] [Full Text] [Related]
33. Hereditary tyrosinemia. Formation of succinylacetone-amino acid adducts.
Manabe S; Sassa S; Kappas A
J Exp Med; 1985 Sep; 162(3):1060-74. PubMed ID: 3928801
[TBL] [Abstract][Full Text] [Related]
34. A GC-MS/MS method for the quantitative analysis of low levels of the tyrosine metabolites maleylacetone, succinylacetone, and the tyrosine metabolism inhibitor dichloroacetate in biological fluids and tissues.
Zolodz MD; Jia M; Liu H; Henderson GN; Stacpoole PW
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jun; 837(1-2):125-32. PubMed ID: 16713404
[TBL] [Abstract][Full Text] [Related]
35. Diet therapy for inborn errors of amino acid metabolism.
Efron ML
J Am Diet Assoc; 1967 Jul; 51(1):40-5. PubMed ID: 6027632
[No Abstract] [Full Text] [Related]
36. Two siblings with tyrosinaemia type 2.
Aydin OF; Zorlu P; Kunak B; Tezic T; Eken A
Eur J Pediatr; 2003 Feb; 162(2):81-3. PubMed ID: 12548382
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of delta-aminolaevulinic acid excretion in random urine samples of children.
Hudák A; Kiss G; Náray M; Süveges E
Eur J Pediatr; 1994 Mar; 153(3):187-9. PubMed ID: 8181504
[TBL] [Abstract][Full Text] [Related]
38. The antenatal diagnosis and aid to the management of hereditary tyrosinaemia by use of a specific and sensitive GC-MS assay for succinylacetone.
Pettit BR; MacKenzie F; King GS; Leonard JV
J Inherit Metab Dis; 1984; 7 Suppl 2():135-6. PubMed ID: 6434868
[No Abstract] [Full Text] [Related]
39. Hematin therapy for the neurologic crisis of tyrosinemia.
Rank JM; Pascual-Leone A; Payne W; Glock M; Freese D; Sharp H; Bloomer JR
J Pediatr; 1991 Jan; 118(1):136-9. PubMed ID: 1986081
[No Abstract] [Full Text] [Related]
40. The pre- and post-natal diagnosis of tyrosinemia type I and the detection of the carrier state by assay of fumarylacetoacetase.
Kvittingen EA; Brodtkorb E
Scand J Clin Lab Invest Suppl; 1986; 184():35-40. PubMed ID: 3473612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
